Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:BPTHNASDAQ:OHRPNASDAQ:ONCSNASDAQ:SBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$4.93+3.8%$5.40$1.01▼$7.42$80.62M2.22140,713 shs102,247 shsBPTHBio-Path$2.49-7.1%$5.01$2.46▼$44.80$1.82M0.354.40 million shs163,632 shsOHRPOHR Pharmaceutical$0.42$7.37$1.60▼$6.28$1.19M0.84180,228 shs21,218 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/AThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics+3.79%+16.00%-14.56%+1.86%+230.89%BPTHBio-Path-7.26%-22.91%-35.58%-73.17%-90.78%OHRPOHR Pharmaceutical0.00%+0.26%-57.90%-30.07%+197.53%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-70.60%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.2693 of 5 stars3.53.00.00.00.61.70.0BPTHBio-Path1.3586 of 5 stars3.52.00.00.02.30.00.6OHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00285.40% UpsideBPTHBio-Path3.00Buy$40.001,506.43% UpsideOHRPOHR PharmaceuticalN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest SBPH, BPTH, OHRP, ONCS, and ALRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ABPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AOHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)BPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)OHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ASBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/ALatest SBPH, BPTH, OHRP, ONCS, and ALRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17BPTHBio-PathN/A1.601.60OHRPOHR PharmaceuticalN/A3.733.73ONCSOncoSec MedicalN/A0.890.89SBPHSpring Bank PharmaceuticalsN/A5.115.11OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%BPTHBio-Path5.74%OHRPOHR Pharmaceutical10.70%ONCSOncoSec Medical8.69%SBPHSpring Bank Pharmaceuticals17.17%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%BPTHBio-Path3.05%OHRPOHR Pharmaceutical12.50%ONCSOncoSec Medical1.32%SBPHSpring Bank Pharmaceuticals12.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableBPTHBio-Path10680,000658,000OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableSBPH, BPTH, OHRP, ONCS, and ALRN HeadlinesSourceHeadlineWhen will interest rates go down?thetimes.co.uk - January 31 at 12:12 PMBank of Canada expected to 'cautiously' start cutting rates in spring: Deloitte Canadaca.finance.yahoo.com - January 6 at 2:22 PMMan stabbed during street fight in Spring Bank Westhulldailymail.co.uk - September 29 at 8:36 AMWhen is the next Bank Holiday and how many are left in 2023?dailyecho.co.uk - August 13 at 4:35 AMSpring Bank fight involved two feuding families, police believehulldailymail.co.uk - August 8 at 3:14 PMCalls for more police patrols on Spring Bank after fight leaves three in hospitalhulldailymail.co.uk - August 8 at 10:14 AMSpring Bank fight: Six men and a woman held over shocking street violencehulldailymail.co.uk - August 7 at 5:57 AMThe mysterious structure on Spring Bank created to shoot out a beam of lighthulldailymail.co.uk - August 5 at 10:31 AMSyria’s Economic Outlook- Spring 2016worldbank.org - July 23 at 2:47 PMHoliday spending by bank’s customers jumped by 40% annually this springindependent.co.uk - July 17 at 9:22 AMHull's Spring Bank set for major regeneration as plans announced to make it more 'attractive'hulldailymail.co.uk - June 30 at 12:00 PMSpring 2023 Layoff Tracker: Grubhub Cuts 400 Staffforbes.com - June 14 at 8:29 PMRibchester to host 36th annual Spring Bank marketlancashiretelegraph.co.uk - June 7 at 11:53 PMThree big changes for DWP benefit payments including Spring Bank Holidaybirminghammail.co.uk - June 2 at 7:19 PMWhat shops are open this spring bank holiday Monday 2023?metro.co.uk - May 30 at 9:46 AMDWP benefit payment date changes over Spring bank holiday weekendmetro.co.uk - May 28 at 9:06 AMWhen is the the next UK Bank Holiday and how many are left in 2023?uk.news.yahoo.com - May 20 at 4:36 PMWorld Bank, IMF Spring Meetings 2023: What did FMs, central bank governors discuss?moneycontrol.com - April 23 at 3:11 PMThe three bank holidays in May as King's Coronation approachesmanchestereveningnews.co.uk - April 23 at 3:11 PMKing's Coronation bank holiday weekend could get workers 10 days off with just 4 days leavemanchestereveningnews.co.uk - April 21 at 11:06 PMIMF and World Bank Spring Meetings, NRA-ILA Leadership Forum, UN in Libya, and Morecfr.org - April 18 at 9:11 AMWorld Bank, IMF spring meetings get underway in complex economic environmentchannelnewsasia.com - April 18 at 9:11 AMSpring sales 2023: Best deals to shop this Easter bank holidayaol.co.uk - April 10 at 10:13 AMWhen are the bank holidays around the King's coronation?manchestereveningnews.co.uk - April 8 at 10:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Bio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Spring Bank PharmaceuticalsNASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.